Canadian Space Agency (CSA) astronaut Joshua Kutyrk is scheduled to launch from Cape Canaveral, Florida, on October 1, accompanied by innovative Canadian technology. The challenges of living and working in space, where the human body is not naturally adapted to low gravity, can lead to various health issues, including the formation of dangerous blood clots. To address this concern, NASA is collaborating with the CSA to enhance astronaut safety on the International Space Station (ISS).
The CSA’s director of the astronaut office, Mathieu Caron, highlighted the importance of understanding the risks associated with prolonged space missions, particularly regarding blood clot formation. In response to these concerns, NASA has partnered with Vancouver-based Response Biomedical to utilize their cutting-edge technology.
One of the key devices developed by Response Biomedical is capable of measuring D-dimer levels in the blood, a crucial indicator of clotting activity. Known as Acute Care Testing in Space (ACTIS), this technology, derived from the company’s RAMP platform, offers rapid and efficient testing for not only blood clots but also conditions like heart attacks and infectious diseases such as COVID-19 and RSV.
The portability and quick turnaround time of the ACTIS device make it a valuable tool for space missions and remote communities on Earth where timely medical assessments are vital. CEO Taso Tsonis emphasized the significance of this Canadian innovation being utilized globally and its potential applications beyond the ISS, possibly extending to future missions to the moon or Mars.
The selection of ACTIS for space exploration represents a notable achievement for Canada, showcasing the adaptability and enduring value of Canadian technology in the realm of space science and healthcare advancements.